Automated insulin delivery after beta-cell replacement failure in people living with type 1 diabetes - 27/04/25
, Sandrine Lablanche b, Luc Rakotoarisoa c, Orianne Villard d, Jean-Pierre Riveline e, Jean-Baptiste Julla e, Fanny Buron f, Sophie Reffet g, Eric Renard d, Laurence Kessler c, Pierre-Yves Benhamou bon behalf of the
GRAGIL network†
ABSTRACT |
Aims |
Patients living with highly unstable type 1 diabetes (T1D) are eligible for beta-cell replacement (βCR) therapy (islet or pancreas transplantation). This study aimed to evaluate glycemic control in patients treated with automated insulin delivery (AID) following failed βCR therapy, defined as secondary graft failure or marginal function.
Material and Methods |
A national, multicenter, retrospective study was conducted with 23 patients who had βCR failure treated with AID for at least three months. The primary outcome was the proportion of patients achieving recommended glucose targets (time in 70–180mg/dl range [TIR] > 70 %, time below range [TBR] < 4 % and HbA1c < 7 %). Secondary outcomes included TIR, glycemia risk index (GRI), HbA1c, coefficient of variation (CV), body weight, insulin doses, severe hypoglycemia and AID discontinuation.
Results |
The proportion of patients achieving recommended glucose targets under AID increased from 5.0 % to 57.1 % after 12 months. TIR increased from 54.2 ± 18.0 % to 75.5 ± 9.6 % after 12-month AID, while GRI decreased from 45.8 ± 22.2 % to 25.6 ± 10.3 %. HbA1c levels decreased from 7.5 ± 0.9 % to 7.0 ± 1.1 % after 12-month AID. CV, body weight and insulin doses did not change. All patients were free from severe hypoglycemia under AID, including those who had experienced severe hypoglycemia after βCR failure. No patient discontinued the AID.
Conclusions |
This study highlights the effectiveness of AID in achieving glucose control targets and preventing severe hypoglycemia in patients with T1D following βCR failure. AID may serve as a valuable therapeutic option to improve glucose control when graft function declines.
Le texte complet de cet article est disponible en PDF.Keywords : Automated insulin delivery, Beta cell replacement, Islet transplantation, Pancreas transplantation, Unstable diabetes
Plan
Vol 51 - N° 4
Article 101654- juillet 2025 Retour au numéro
Article précédent
- Increased fatty acid-binding protein 4 levels are associated with the risk of developing retinopathy in type 2 diabetes mellitus patients
- Yan Liu, Kaihui Ma, Aiying Zhang, Yun Cui, Hui Zhao, Xinhua Li, Ke Zhao
- Musculoskeletal disorders in type 1 diabetes: Clinical phenotyping and associations with quality of life and glucose control - The French SFDT1 cohort study
- Noémie Topalian, Sylvie Picard, Jean-Pierre Riveline, Dulce Canha, Jean-Baptiste Julla, Sandrine Lablanche, Laurence Salle, Emmanuel Sonnet, Aurélie Berot, Didier Gouet, Kalliopi Bilariki, Chloé Amouyal, Lucien Marchand, Sophie Borot, Nicolas Chevalier, Isabela Banu, Emmanuelle Sokol, Emmanuel Cosson, Guy Fagherazzi, Gloria Aguayo, SFDT1 study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?